Dr Indunil Weerasena | Medical Oncologist | Icon Cancer Centre

Dr Indi Weerasena

Medical Oncologist
Become a Patient

Dr Indi (Indunil) Weerasena brings a holistic, evidence-based and compassionate approach to his practice that ensures his patients receive the highest quality treatment and feel empowered throughout their care.


Dr Weerasena received his medical training locally in Perth.  He completed initial physician training at Sir Charles Gairdner Hospital and Royal Perth Hospital, followed by specialist medical oncology training at Fiona Stanley Hospital and Sir Charles Gairdner Hospital.

Before becoming a fellow of the Royal Australasian College of Physicians (FRACP), he was awarded a Cancer Council research grant with the WA Cancer Network where he contributed to research in identifying a highly aggressive and difficult-to-detect form of breast cancer.

Dr Weerasena is passionate about continually improving the quality of care delivered to patients living with cancer.  He has contributed to multiple international research projects and provided input into the development of several cancer treatment protocols in Australia.  He is also an active member of several leading international and national oncological societies and tumour boards.

His clinical experience covers a wide range of solid tumour malignancies, and he has a special interest in breast, lung, melanoma and other skin cancers, gynaecological, head and neck, gastrointestinal and urological cancers.

Affiliations & Memberships

  • Royal Australasian College of Physicians (RACP)

Special Interests

Dr Indi Weerasena accepts referrals for all cancer types, with a special clinical interest in:
  • Breast cancer
  • Gastrointestinal cancer
  • Lung cancer
  • Skin cancer
  • Urological cancer

Icon Locations

Rockingham View centre


    • Redfern, A., Weerasena, I., Spalding, L., Ong, M., Golden, E., Woodward, E. & Blancafort, P. (2023). Abstract P1-13-13: Nuclear envelope Expression of the Oncogene Adipocyte-Associated Methionine Domain Containing Conveys Inferior Prognosis but Increased Sensitivity to Statins and Fluorouracil-Based Therapy. Cancer Research. 83. P1-13.
    • Weerasena, I., Spalding, L., Dessauvagie, B., Golden, E., Woodward, E., Blancafort, P. & Redfern, A. (2022). Abstract P5-05-03: Adipocyte associated methionine domain containing (AAMDC): A nuclear envelope protein with predictive and prognostic potential in luminal breast cancer. Cancer Research. 82. P5-05.
    • Weerasena, I., Spalding, L., Martin, H. & Redfern, A. (2020). 53P Aromatase inhibitor and cyclin-dependent kinase 4/6 inhibitor treated HR+/HER2- metastatic breast cancer differ to those treated with Aromatase inhibitors alone on progression. Annals of Oncology. 31. S1263.
    • Fysh, E., Tan, S., Read, C., Lee, F., McKenzie, K., Olsen, N., Weerasena, I., Threlfall, T., Klerk, N., Musk, A. & Lee, Y C G. (2013). Pleurodesis outcome in malignant pleural mesothelioma. Thorax. 68(6).
    • Fysh, Edward & Tan, Sheena Kate & Read, Catherine & Lee, Felicity & Mackenzie, K. & Weerasena, Indunil & Musk, A. & Lee, YC G. (2012). Outcome of Pleurodesis for Malignant Effusions in Mesothelioma. Respirology. 17. 56-56.